Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 1:40 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1225–1248 of 3,545 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Infant Clear all
Completed No phase listed Observational Accepts healthy volunteers

Point-of-Care System for Determination of Bilirubin Capacity in Neonates

NCT02612207
View directory record Official record
Conditions
Jaundice, Neonatal, Hyperbilirubinemia, Bilirubin-Induced Neurological Dysfunction (BIND)
Interventions
Bilirubin Binding Capacity by Hematofluorometry Validation
Device
Lead sponsor
Stanford University
Other
Eligibility
6 Hours to 14 Days
Enrollment
161 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
2
States / cities
Stanford, California • Lakewood, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 28, 2021 · Synced Oct 30, 2026, 1:40 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

The Effects of Pacifier-Activated Lullaby on Oral Feeding Among Preterm Infants

NCT07819734
View directory record Official record
Conditions
Dysphagia of Newborn
Interventions
Pacifier-Activated Lullaby (PAL) Therapy
Device
Lead sponsor
Nemours Children's Clinic
Other
Eligibility
34 Weeks to 36 Weeks
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2027
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 30, 2026, 1:40 PM EDT
Active, not recruiting Phase 3 Interventional

A Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination Therapy

NCT05444257
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
VX-121/TEZ/D-IVA
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
12 Years and older
Enrollment
822 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
72
States / cities
Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 65 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 30, 2026, 1:40 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Evaluation of Responses to Fluzone® in Infants ≥ 6 Months of Age Who Did or Did Not Receive Fluzone® at 2 Months of Age

NCT00885105
View directory record Official record
Conditions
Influenza
Interventions
Influenza Virus Vaccine
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
6 Months to 11 Months
Enrollment
242 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
6
States / cities
Little Rock, Arkansas • Marietta, Georgia • Durham, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2016 · Synced Oct 30, 2026, 1:40 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Community-based Obesity Treatment in African American Women After Childbirth

NCT02829229
View directory record Official record
Conditions
Obesity, Overweight
Interventions
Community-based obesity treatment (PP)
Behavioral
Lead sponsor
Temple University
Other
Eligibility
18 Years and older · Female only
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 7, 2022 · Synced Oct 30, 2026, 1:40 PM EDT
Completed No phase listed Observational

Using MRI to Observe Lung Changes in Infants With CF Compared to Infants Without CF

NCT01832519
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Not listed
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
6 Months to 52 Months
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 23, 2017 · Synced Oct 30, 2026, 1:40 PM EDT
Completed No phase listed Observational

Study of Shunt Flow Sensor Accuracy in Extra-ventricular Drains.

NCT01108965
View directory record Official record
Conditions
Hydrocephalus, Nervous System Diseases, Infant, Newborn Diseases
Interventions
Not listed
Lead sponsor
Transonic Systems Inc.
Industry
Eligibility
Not listed
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated May 27, 2016 · Synced Oct 30, 2026, 1:40 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics of Thiamine in Breastfeeding Mothers and Infants

NCT01864057
View directory record Official record
Conditions
Beriberi
Interventions
thiamine hydrochloride 100 mg
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 29, 2013 · Synced Oct 30, 2026, 1:40 PM EDT
Recruiting Not applicable Interventional

Parent Navigator Program (PNP) to Improve Outcomes in Latino/x Children and Parents

NCT07023367
View directory record Official record
Conditions
Congenital Heart Disease
Interventions
Parent Navigator Program, Standard of Care
Behavioral
Lead sponsor
Children's Hospital Los Angeles
Other
Eligibility
0 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 12, 2025 · Synced Oct 30, 2026, 1:40 PM EDT
Recruiting Not applicable Interventional

A Randomized Controlled Trial of Impact of Wearable, Wireless Breast Pumps on Frequency and Efficacy of Milk Expression in Mothers of Premature Infants

NCT06723067
View directory record Official record
Conditions
Premature Birth
Interventions
Wearable wireless breast pump
Device
Lead sponsor
University of Texas at Austin
Other
Eligibility
Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Dec 9, 2024 · Synced Oct 30, 2026, 1:40 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Genesis Electrical Impedance Tomography (EIT): A Preliminary Study

NCT03797183
View directory record Official record
Conditions
Premature Infant, Chronic Respiratory Disease, Neuromuscular Diseases, Healthy, Bronchopulmonary Dysplasia, Pulmonary Vein Stenoses
Interventions
Not listed
Lead sponsor
University of Colorado, Denver
Other
Eligibility
14 Days to 40 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2026
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Nov 13, 2025 · Synced Oct 30, 2026, 1:40 PM EDT
Completed Phase 4 Interventional

The Effectiveness of Oral Dexamethasone for Acute Bronchiolitis

NCT00119002
View directory record Official record
Conditions
Bronchiolitis, Viral
Interventions
dexamethasone, Placebo
Drug
Lead sponsor
University of Utah
Other
Eligibility
2 Months to 11 Months
Enrollment
598 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 14, 2008 · Synced Oct 30, 2026, 1:40 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Tdap Vaccination for Infant Caregivers

NCT01233401
View directory record Official record
Conditions
Pertussis, Vaccination
Interventions
Survey
Other
Lead sponsor
Yale University
Other
Eligibility
18 Years to 64 Years
Enrollment
102 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 28, 2011 · Synced Oct 30, 2026, 1:40 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Evaluation of a Smartphone-based Screening Tool (Picterus JP) for Neonatal Jaundice (Chicago)

NCT05521607
View directory record Official record
Conditions
Neonatal Jaundice
Interventions
Picterus Jaundice Pro (JP)
Device
Lead sponsor
Picterus AS
Industry
Eligibility
1 Day to 14 Days
Enrollment
250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 30, 2026, 1:40 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

MRI for Non-Invasive Imaging in Neonates and Children

NCT02163681
View directory record Official record
Conditions
Healthy, Cystic Fibrosis (CF), Asthma, Bronchopulmonary Dysplasia (BPD)
Interventions
Hyperpolarized Helium-3 MRI of the chest
Drug
Lead sponsor
University of Virginia
Other
Eligibility
4 Months to 65 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2018
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 19, 2022 · Synced Oct 30, 2026, 1:40 PM EDT
Completed Phase 1 Interventional

Evaluation of Single Ascending Doses of Subcutaneous Exendin 9-39 in Patients With Post-Bariatric Hypoglycemia

NCT02996812
View directory record Official record
Conditions
Hyperinsulinemia Hypoglycemia
Interventions
Exendin (9-39)
Drug
Lead sponsor
Tracey McLaughlin
Other
Eligibility
18 Years to 65 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Dec 4, 2024 · Synced Oct 30, 2026, 1:40 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

BM Characterization Pilot

NCT03138057
View directory record Official record
Conditions
Diaper Rash
Interventions
Not listed
Lead sponsor
Kimberly-Clark Corporation
Industry
Eligibility
Up to 12 Months
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Jan 18, 2018 · Synced Oct 30, 2026, 1:40 PM EDT
Completed Phase 2 Interventional

Phase II Randomized Study of Tin Mesoporphyrin for Neonatal Hyperbilirubinemia

NCT00004381
View directory record Official record
Conditions
Glucosephosphate Dehydrogenase Deficiency, Hyperbilirubinemia, Hemolytic Disease of Newborn
Interventions
tin mesoporphyrin
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
0 Years to 24 Hours
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
2
States / cities
Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 30, 2026, 1:40 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Mothers and Others: Family-based Obesity Prevention for Infants and Toddlers

NCT01938118
View directory record Official record
Conditions
Obesity
Interventions
Obesity Prevention Group, Injury Prevention Group
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
Not listed
Enrollment
430 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2017
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 19, 2018 · Synced Oct 30, 2026, 1:40 PM EDT
Completed Phase 4 Interventional

Efficacy and Satisfaction Comparing Two Braces in the Treatment of Developmental Dysplasia of the Hip (DDH) in Infants

NCT01375218
View directory record Official record
Conditions
Hip Dislocation, Congenital, Congenital Deformity of Hip Joint
Interventions
Pavlik Brace, Plastizote Brace
Other
Lead sponsor
OrthoCarolina Research Institute, Inc.
Other
Eligibility
Up to 2 Months
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 19, 2015 · Synced Oct 30, 2026, 1:40 PM EDT
Approved For Marketing No phase listed Expanded access

Expanded Access of Omegaven IV Fat Emulsion to Infants and Children With PNALD

NCT02929303
View directory record Official record
Conditions
Total Parenteral Nutrition-induced Cholestasis
Interventions
Omegaven IV lipid emulsion
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
Up to 17 Years
U.S. locations
1
States / cities
Park Ridge, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 30, 2026, 1:40 PM EDT
Completed Phase 2 Interventional Results available

Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies

NCT01529827
View directory record Official record
Conditions
Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Grade III Lymphomatoid Granulomatosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Aplastic Anemia, Burkitt Lymphoma, Childhood Acute Lymphoblastic Leukemia in Remission, Childhood Acute Myeloid Leukemia in Remission, Childhood Chronic Myelogenous Leukemia, Childhood Diffuse Large Cell Lymphoma, Childhood Grade III Lymphomatoid Granulomatosis, Childhood Immunoblastic Large Cell Lymphoma, Childhood Myelodysplastic Syndromes, Childhood Nasal Type Extranodal NK/T-cell Lymphoma, Chronic Myelomonocytic Leukemia, Chronic Phase Chronic Myelogenous Leukemia, Congenital Amegakaryocytic Thrombocytopenia, Diamond-Blackfan Anemia, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Hepatosplenic T-cell Lymphoma, Juvenile Myelomonocytic Leukemia, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Nodal Marginal Zone B-cell Lymphoma, Paroxysmal Nocturnal Hemoglobinuria, Peripheral T-cell Lymphoma, Polycythemia Vera, Post-transplant Lymphoproliferative Disorder, Previously Treated Myelodysplastic Syndromes, Primary Myelofibrosis, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Grade III Lymphomatoid Granulomatosis, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Adult T-cell Leukemia/Lymphoma, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Recurrent Childhood Anaplastic Large Cell Lymphoma, Recurrent Childhood Grade III Lymphomatoid Granulomatosis, Recurrent Childhood Large Cell Lymphoma, Recurrent Childhood Lymphoblastic Lymphoma, Recurrent Childhood Small Noncleaved Cell Lymphoma, Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Recurrent Small Lymphocytic Lymphoma, Recurrent/Refractory Childhood Hodgkin Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Hairy Cell Leukemia, Refractory Multiple Myeloma, Secondary Acute Myeloid Leukemia, Secondary Myelodysplastic Syndromes, Secondary Myelofibrosis, Severe Combined Immunodeficiency, Severe Congenital Neutropenia, Shwachman-Diamond Syndrome, Splenic Marginal Zone Lymphoma, T-cell Large Granular Lymphocyte Leukemia, Waldenstrom Macroglobulinemia, Wiskott-Aldrich Syndrome
Interventions
fludarabine phosphate, melphalan, total-body irradiation, tacrolimus, mycophenolate mofetil, methotrexate, laboratory biomarker analysis, allogeneic hematopoietic stem cell transplantation, peripheral blood stem cell transplantation
Drug · Radiation · Other + 1 more
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
3 Years to 75 Years
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Sep 24, 2019 · Synced Oct 30, 2026, 1:40 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Study to Demonstrate the Efficacy and Safety of Propranolol Oral Solution in Infants With Proliferating Infantile Hemangiomas Requiring Systemic Therapy

NCT01056341
View directory record Official record
Conditions
Infantile Hemangioma
Interventions
Propranolol, Placebo
Drug
Lead sponsor
Pierre Fabre Dermatology
Industry
Eligibility
35 Days to 150 Days
Enrollment
512 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
10
States / cities
Irvine, California • Redwood City, California • San Diego, California + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2015 · Synced Oct 30, 2026, 1:40 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Safety, Tolerability, and Immunogenicity of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Healthy Infants

NCT05844423
View directory record Official record
Conditions
Pneumococcal Vaccines
Interventions
0.5 ml dose of 1.1 mcg VAX-24, 0.5 ml dose of PCV20, 0.5 ml dose of 2.2 mcg VAX-24, 0.5 ml dose of 2.2/4.4 mcg VAX-24
Biological
Lead sponsor
Vaxcyte, Inc.
Industry
Eligibility
42 Days to 89 Days
Enrollment
802 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
32
States / cities
Jonesboro, Arkansas • Madera, California • Tampa, Florida + 22 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2025 · Synced Oct 30, 2026, 1:40 PM EDT